Cat. No.: DAB-0011849
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Mouse, Rat |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ser60 of BNIP3 from mouse/rat. Antibodies were purified by peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | Bnip3 |
| UniProt No. | O55003 |
| Gene ID | 12176 |
| Gene Description | BNIP3 is a pro-apoptotic mitochondrial protein and Bcl-2 family member that contains a Bcl-2 homology 3 domain and a carboxyl-terminal transmembrane domain. While BNIP3 has a predicted molecular weight of about 22 kDa, it runs anomalously on SDS-PAGE and includes a band of around 60 kDa that may be a dimeric form that is not reduced. BNIP3 associates with anti-apoptotic family members Bcl-2, Bcl-xL, and the adenovirus homologue E1B-19kDa. BNIP3 is distinct from other Bcl-2 family members that contain only the BH3 domain in that the TM domain, and not the BH3 domain, is required for mitochondrial targeting and pro-apoptotic activity. In addition to apoptosis, BNIP3 has been implicated in necrosis and autophagy. In hypoxic conditions, BNIP3 can induce mitochondrial autophagy by disrupting the Bcl-2-Beclin-1 complex. BNIP3 can also promote mitophagy by triggering the translocation of the E3 ubiquitin ligase Parkin to the mitochondria or by directly binding LC3 on the autophagosome. BNIP3 may also localize to the endoplasmic reticulum where it can selectively induce the autophagic clearance of ER. Increased expression of BNIP3 under hypoxic conditions is mainly regulated by the transcription factor HIF-1α. Silencing of the BNIP3 promoter by methylation has been observed in several types of cancer cells and may play an important role in their survival. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
